Chd clinical trials

Explore recruiting chd clinical trials.

Recruiting chd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Latvia, Italy, Estonia, Czechia, Finland, Netherlands +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

France, Denmark, Hungary, Italy, Netherlands, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

Bulgaria

Phase II and Phase III (Integrated) EU CTIS Study details

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease

Hungary, Czechia, Sweden, Italy, Netherlands, Germany +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.

Italy, Romania, Germany, Bulgaria

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Chd trials by city

Chd in Toronto Chd in Vancouver Chd in Montreal Chd in Calgary Chd in Edmonton Chd in Ottawa Chd in Winnipeg Chd in Quebec City Chd in Hamilton Chd in Kitchener Chd in London Chd in Halifax Chd in New York Chd in Los Angeles Chd in Chicago Chd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease